Abstract
Drug resistance is a major hurdle in the global battle against tuberculosis (TB). In tackling this problem it is important to understand both how resistance emerges as well as the ways in which multi-drug and extensively drug-resistant TB (M/XDR-TB) may be successfully treated. The biggest problem with treatment is the lack of effective drugs. Exciting developments have been made in this area over recent years with useful drugs being found from older agents as well as new discoveries. Patent applications are being made for novel agents and are also possible as new use for older agents such as thioridazine. A flourishing drug pipeline is critical if we are to make progress in the management of M/XDR-TB.
| Original language | English |
|---|---|
| Pages (from-to) | 77 |
| Number of pages | 83 |
| Journal | Recent Patents Anti-infective Drug Discovery |
| Volume | 6 |
| Issue number | 2 |
| Publication status | Published - 31 May 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- tuberculosis
- MDR
- XDR
- New Therapy
- Drug Discovery
Fingerprint
Dive into the research topics of 'XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver